Y-mAbs Therapeutics, a Phase 2 biotech developing monoclonal antibody therapies for pediatric cancers, raised $96 million by offering 6.0 million shares at $16, the high end of the $14 to $16 range. The company had originally planned to raise $80 million by selling 5.3 million shares.
Y-mAbs Therapeutics plans to list on the Nasdaq under the symbol YMAB. BofA Merrill Lynch and Cowen acted as lead managers on the deal.
